Lupus & antiphospholipid syndrome
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework
Authors' conclusion
APS remains underdiagnosed, inconsistently managed and inadequately represented in both policy and education.
Study context
- Population
- Purposively sampled stakeholders in antiphospholipid syndrome (APS) care across Europe (clinicians of different specialties, researchers, policy professionals, laboratory experts, trialists, nurses, students and trainees), within ReCONNET
- Participants
- 16 interviews
- Outcome
- Stakeholder-identified gaps in APS care (clinical, systemic and educational/research-related unmet needs)
Methodological detailssemistructured interviews, purposive sampling, thematic analysis, Interviews conducted between February and April 2025
- Semistructured interviews
- Purposive sampling
- Thematic analysis
- Interviews conducted between February and April 2025
Main finding
As reported in the abstract
Stakeholder-identified unmet needs in APS care
- Delayed diagnosis cited as a major barrier
- Over 85%
- Limitations of current classification criteria in capturing all clinical settings of APS
- 11
- Lack of access to multidisciplinary teams as a barrier to optimal care
- 75% (12 out of 16)
- Warfarin remains mainstay of therapy despite adherence and monitoring challenges
- 9
- Need for integration across national or European APS registries and insufficient integration in rare disease policy frameworks
- 12
- Educational stakeholders noting minimal curricular exposure to APS
- 100%
Original publication
Unmet needs and challenges in the diagnosis and management of antiphospholipid syndrome: a qualitative stakeholder study within the ReCONNET framework. Lupus Sci Med. Published 9 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →